OncoMatch/Clinical Trials/NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Is NCT05614739 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for urinary bladder neoplasms.
Treatment: Vepugratinib · Pembrolizumab · enfortumab vedotin · Trastuzumab Deruxtecan · Midazolam · Digoxin · Rosuvastatin — The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: FGFR3 alteration
qualifying FGFR3 alteration
Required: HER2 (ERBB2) expression
expression of human epidermal growth factor receptor 2 (HER2)
Prior therapy
Must have received: FGFR inhibitor (erdafitinib)
have received prior erdafitinib
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona - Cancer Center · Tucson, Arizona
- City of Hope · Duarte, California
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology · Los Angeles, California
- University of California - Irvine · Orange, California
- University of California (UC) Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05614739 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received FGFR inhibitor.
Does this trial require FGFR3?
Yes, FGFR3 alteration is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify